Mostra el registre parcial de l'element

dc.contributor.authorMonje, Alberto
dc.contributor.authorGalindo-Fernández, Pablo
dc.contributor.authorNart, José
dc.date.accessioned2024-05-23T09:38:10Z
dc.date.available2024-05-23T09:38:10Z
dc.date.issued2024
dc.identifier.citationMonje, Alberto; Galindo-Fernández, Pablo; Nart, José [et al.]. Supportive therapy following peri-implantitis treatment: a retrospective study on compliance. Clinical Oral Implants Research, 2024, p. 1-8. Disponible en: <https://onlinelibrary.wiley.com/doi/10.1111/clr.14257>. Fecha de acceso: 23 may. 2024. DOI: 10.1111/clr.14257ca
dc.identifier.issn0905-7161ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/4247
dc.description.abstractBackground: The compliance rate with supportive therapy following peri-implantitis treatment (SPIT) remains unknown. The present retrospective study was carried out to assess the compliance rate and the factors influencing compliance in a private practice setting. Materials and Methods: Patients were divided into three groups according to compliance rate: regular compliance (RC ≥2 SPIT/year), erratic compliance (EC <2 SPIT/year), and non-compliance (NC <1 SPIT/year). Overall, 17 patient- (n = 8) and site-related variables (n = 9) were explored as potential confounders of compliance. The Chi2 test was applied to assess the association between categorical variables and determine the odds ratio (OR). Results: The study comprised 159 patients restored with 1075 implants, of which 469 were treated for peri-implantitis and met the inclusion criteria. A total of 57.2% were RC, 25.8% EC, and 17% NC. The multivariate analysis showed that smoking and grade C periodontitis reduced the likelihood of RC (OR = 0.28, p < .001) when compared to complete edentulism or non-smoking. Moreover, age demonstrated being associated with follow-up when SPIT was interrupted in EC and NC (OR = 0.94, p = .007). Conclusion: Comprehensive information, provided prior to peri-implantitis treatment, regarding the importance of adhering to SPIT after peri-implantitis treatment to achieve/maintain peri-implant health, resulted in ~60% regular compliance rate (NCT05772078).ca
dc.format.extent9ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofClinical Oral Implants Researchca
dc.rights© 2024 The Authors. Clinical Oral Implants Research published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproductionin any medium, provided the original work is properly cited and is not used for commercial purposes.ca
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherImplants dentalsca
dc.subject.otherPeriimplantitisca
dc.subject.otherMalaltia periodontalca
dc.subject.otherImplantes dentalesca
dc.subject.otherPeriimplantitisca
dc.subject.otherEnfermedad periodontalca
dc.subject.otherDental implantsca
dc.subject.otherPeri-implantitisca
dc.subject.otherPeriodontal diseaseca
dc.titleSupportive therapy following peri-implantitis treatment: a retrospective study on complianceca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc616.3ca
dc.identifier.doihttps://dx.doi.org/10.1111/clr.14257ca


Fitxers en aquest element

 

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

© 2024 The Authors. Clinical Oral Implants Research published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproductionin any medium, provided the original work is properly cited and is not used for commercial purposes.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by-nc/4.0/
Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix